FLVCR2 and cancer: Although no clinically approved drugs directly targeting the TRiC/CCT chaperonin complex are currently available, multiple lines of evidence support the concept that TRiC/CCT represents a druggable vulnerability in cancer, particularly in tumors characterized by high proteotoxic and metabolic stress.